CBT earnings analysis
What we found in CBT's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Q3 revenue increased to $982 million, up $59 million year over year and $78 million sequentially, but profitability deteriorated materially: gross profit declined $60 million year over year and GAAP EPS fell to $0.12 from $1.86. Reinforcement Materials’ $31 million EBIT decline, restructuring costs, and a $29 million U.K. pension settlement outweighed an $11 million EBIT improvement in Performance Chemicals. Cash generation remained positive at $126 million of calculated nine-month free cash flow, although operating cash flow fell to $278 million as working capital absorbed $58 million; management also expects sequential Q4 EBIT declines in both segments.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue returned to growth
- Q3 revenue was $982 million, up $59 million year over year and $78 million sequentially from $904 million in Q2. Higher volumes contributed $51 million across the two segments year over year.
- Performance Chemicals expanded earnings
- Performance Chemicals was the offset to weakness in Reinforcement Materials: Q3 sales rose $31 million and segment EBIT increased $11 million, supported by battery-materials and fumed-metal-oxides demand.
- Cash generation remained positive
- Nine-month operating cash flow was $278 million, versus $446 million a year earlier. After $152 million of capital expenditures, calculated nine-month free cash flow was $126 million.
- Liquidity capacity remains substantial
- Liquidity at June 30 included $250 million of cash and cash equivalents plus $1.1 billion of revolver availability. The new $1.3 billion unsecured revolver matures in May 2031.
- Capital returns continued
- The company spent $101 million on share repurchases and $72 million on common dividends in the first nine months, while retaining authorization for 8,069,320 additional shares.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- GAAP earnings dropped sharply
- GAAP net income attributable to Cabot fell to $6 million ($0.12 per diluted share) from $101 million ($1.86) a year earlier. The filing attributes the decline in part to $39 million of higher restructuring expense, a $31 million Reinforcement Materials EBIT decline, and a $29 million U.K. pension-settlement charge.
- Reinforcement pricing and mix remain pressured
- Reinforcement Materials faced $20 million of unfavorable Q3 pricing/product mix, and its EBIT declined $31 million year over year. Management expects segment EBIT to decline modestly sequentially in Q4 due to seasonal volume and regional-mix effects.
- Working capital is absorbing cash
- Nine-month operating cash flow declined $168 million to $278 million as net working capital increased $58 million, largely from higher receivables and inventories. Liquidity also declined $126 million during the nine-month period.
- Sarnia environmental compliance deadline
- The Sarnia, Ontario reinforcing-carbons plant is out of compliance with a sulfur-dioxide air standard and is currently required to install controls by July 1, 2028; an extension request remains under consideration. The supplied 10-Q does not present a formal Item 1A risk-factor amendment versus the 2025 10-K.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.12
- Segment
- Reinforcement Materials: Q3 sales increased $26 million year over year, driven by $33 million of volume and $12 million of FX, partly offset by a $20 million pricing/product-mix decline; segment EBIT fell $31 million.
- Segment
- Performance Chemicals: Q3 sales increased $31 million year over year, driven by $18 million of volume, $7 million of FX and $5 million of pricing/product mix; segment EBIT rose $11 million.
What they said about what is next.
The 10-Q does not provide a numeric revenue or EPS outlook. Management expects both Reinforcement Materials and Performance Chemicals segment EBIT to decline sequentially in Q4 fiscal 2026. Fiscal-2026 capital expenditures are expected to be $200 million to $215 million.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 6, 2026
- Cabot Corporation delivered solid Q2 2026 results, with revenue of $904 million and EPS of $1.61, both exceeding expectations. The Performance Chemicals segment saw growth, partially offsetting declines in Reinforcement…
- 10-K · November 24, 2025
- Cabot reiterates its 'Creating for Tomorrow' growth strategy (introduced early fiscal 2022) while operating two reportable segments: Reinforcement Materials and Performance Chemicals. The company completed a capacity…
- 10-Q · May 7, 2025
- Cabot reported quarterly net sales of $936 million (three months ended March 31, 2025) with gross profit of $241 million and diluted EPS of $1.69. Margins improved (gross ~25.8%, operating ~17.3%) and operating income…
- 10-K · November 20, 2024
- Cabot (CBT) positions itself as a global specialty chemicals and performance materials company organized into two reportable segments (Reinforcement Materials and Performance Chemicals) with a continued growth strategy…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CBT makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever